Haleon PLC Sponsored ADR $HLN Shares Sold by Keystone Financial Planning Inc.

Keystone Financial Planning Inc. trimmed its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 75.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,366 shares of the company’s stock after selling 168,476 shares during the period. Keystone Financial Planning Inc.’s holdings in Haleon were worth $550,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of HLN. Bank of America Corp DE lifted its stake in shares of Haleon by 116.7% during the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after buying an additional 6,669,923 shares during the period. JPMorgan Chase & Co. grew its stake in Haleon by 36.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock worth $107,503,000 after acquiring an additional 3,207,986 shares during the period. Optiver Holding B.V. purchased a new stake in Haleon in the 3rd quarter worth approximately $45,593,000. Raymond James Financial Inc. raised its holdings in Haleon by 14.3% in the 3rd quarter. Raymond James Financial Inc. now owns 4,931,464 shares of the company’s stock valued at $44,235,000 after acquiring an additional 616,284 shares during the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in Haleon by 29.4% in the 3rd quarter. Qube Research & Technologies Ltd now owns 3,124,287 shares of the company’s stock valued at $28,025,000 after acquiring an additional 710,259 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Argus upgraded Haleon to a “strong-buy” rating in a report on Tuesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Finally, HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Stock Performance

Shares of NYSE:HLN opened at $10.08 on Friday. The business has a 50-day moving average of $10.53 and a two-hundred day moving average of $9.88. The firm has a market capitalization of $44.88 billion, a PE ratio of 25.83 and a beta of 0.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. Haleon PLC Sponsored ADR has a 12 month low of $8.71 and a 12 month high of $11.42.

Haleon Announces Dividend

The firm also recently announced a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be given a dividend of $0.1307 per share. This represents a yield of 251.0%. The ex-dividend date of this dividend is Friday, April 10th. Haleon’s dividend payout ratio is 28.21%.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.